GlassScriptPhysician profile
Mandeep Hundal
NPI 1811153489
$7,808.26
in general payments reported to CMS, 2019-2025
34 companies · $1,687 in 2025
The $1,687 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,085 · 2020: $337 · 2021: $721 · 2022: $863 · 2023: $1,554 · 2024: $1,561 · 2025: $1,687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,627 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,626.69 |
| Education | $174.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,307.95 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $2,052.73 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $757.14 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Electromed, INC. | $313.68 | 2022-2025 | Smartvest |
| Regeneron Healthcare Solutions, INC. | $251.02 | 2019-2025 | Dupixent |
| Genzyme Corporation | $204.24 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $190.61 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Sanofi-Aventis U.S. LLC | $184.14 | 2019-2024 | |
| Amgen INC. | $178.28 | 2023-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $130.96 | 2022-2025 | Glassia, Cuvitru |
| Axsome Therapeutics, INC. | $126.91 | 2023-2025 | Sunosi |
| Insmed, INC. | $110.22 | 2019-2025 | Brinsupri, Arikayce |
| Mallinckrodt Hospital Products INC. | $103.30 | 2023-2024 | Acthar |
| Harmony Biosciences LLC | $92.84 | 2021-2023 | Wakix |
| United Therapeutics Corporation | $86.83 | 2022-2025 | Tyvaso, Tyvaso |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $66.64 | 2023-2024 | Eliquis |
| Philips North America LLC | $64.89 | 2019-2025 | Vest Therapy Und |
| Baxter Healthcare | $63.40 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Inogen, INC. | $60.49 | 2024-2025 | |
| Pfizer INC. | $55.21 | 2019-2022 | |
| Lilly USA, LLC | $52.69 | 2025 | Zepbound |
| Advanced Respiratory, INC | $49.29 | 2019 | |
| Abbvie INC. | $44.75 | 2022-2024 | |
| Grifols USA, LLC | $41.71 | 2025 | Prolastin-C Liquid |
| Teva Pharmaceuticals USA, INC. | $40.45 | 2020-2021 | |
| Mylan Specialty L.P. | $25.84 | 2019-2023 | Yupelri |
| Merck Sharp & Dohme LLC | $22.16 | 2020 | |
| Genentech USA, INC. | $21.66 | 2019 | |
| Allergan, INC. | $21.42 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.78 | 2023 | |
| Olympus America INC. | $19.54 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.57 | 2021 | |
| Jazz Pharmaceuticals INC. | $15.18 | 2021 | |
| Cmp Pharma, INC. | $14.74 | 2023 | Carospir, Atorvaliq, Tadliq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mandeep Hundal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.